ovarian disease: A disease involving the ovary.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
210 |
4. Check minimum number of eventsNone |
210 |
5. Include endpointsNone |
210 |
6. Filter based on genotype QC (FinnGen only) |
210 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Ovarian dysfunction, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Ovarian dysfunction
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1225 | 1225 | - |
| Only index persons | 1157 | 1157 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | - |
| Only index persons | 0.04 | 0.04 | - |
| Median age at first event (years) | |||
| Whole population | - | 32.36 | - |
| Only index persons | - | 31.95 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 210 | 210 | - |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | - |
| Median age at first event (years) | 32.98 | 32.98 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 180
- Matched controls
- 1800
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E28.8
ICD-10 Finland
Other ovarian dysfunction
+∞
89.2
78
*
E28.9
ICD-10 Finland
Ovarian dysfunction, unspecified
+∞
52.7
48
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
85.7
46.0
50
8
E28.3
ICD-10 Finland
Primary ovarian failure
+∞
32.3
30
*
25691
ICD-8 Finland
NA
+∞
20.2
19
*
G03FB08
ATC
dydrogesterone and estrogen; systemic (progestogens and estrogens, sequential prep.)
8.6
19.3
44
65
25699
ICD-8 Finland
Ovarian dysfunction, Other and unspecified
+∞
19.1
18
*
25698
ICD-8 Finland
Ovarian dysfunction, Alia definita
+∞
15.9
15
*
G03CA03
ATC
estradiol; nasal, systemic, rectal, transdermal, vaginal
3.4
13.6
116
628
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.9
10.4
101
557
H02AB09
ATC
hydrocortisone; systemic
16.2
9.7
15
10
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
38.8
9.1
11
*
N91.1
ICD-10 Finland
Secondary amenorrhoea
8.4
8.9
19
25
62800
ICD-8 Finland
Sterility, female, Sterilitas primaria
21.3
8.6
12
6
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
5.7
7.9
22
43
N91.4
ICD-10 Finland
Secondary oligomenorrhoea
21.0
7.2
10
5
R4110
NOMESCO Finland
Physiotherapy
2.7
7.1
54
245
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.2
7.0
16
24
G03DA02
ATC
medroxyprogesterone; systemic (pregnen (4) derivatives)
3.9
6.9
28
81
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
6.3
6
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.3
6
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
8.1
6.2
13
17
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
45
52
10.74
37.21
1.5
1.1
20.7
9.6
u/l
3.08
35
43
36
47
9.04
26.80
1.6
1.3
0.3
0.5
nmol/l
1.41
25
39
38
54
8.37
26.39
1.7
1.2
2.1
2.7
ug/l
0.39
24
48
52
140
4.61
18.35
1.9
1.2
36.8
24.3
iu/l
1.39
46
118
74
419
2.18
6.39
3.7
2.9
0.3
0.4
e6/l
0.61
56
306
13
29
4.71
5.59
4.0
2.7
3.6
4.8
e9/l
0.94
13
29
13
29
4.71
5.59
4.1
3.3
55.7
58.6
%
0.32
13
29
21
68
3.32
5.51
4.0
5.2
24.5
25.0
mmol/l
0.22
21
68
85
531
2.01
5.51
3.5
2.9
—
—
—
0
0
82
521
1.94
4.96
4.2
2.9
2.4
2.4
mmol/l
0.07
72
462
93
618
1.91
4.90
6.0
3.8
36.5
36.8
g/l
0.23
85
581
134
1015
1.88
4.58
14.1
8.1
3.9
3.9
e9/l
0.04
116
890
90
605
1.85
4.48
1.8
1.8
82.8
97.1
pmol/l
1.98
40
302
121
899
1.82
4.29
5.0
3.8
6.4
6.3
mmol/l
0.35
113
800
178
1508
2.18
4.11
5.6
4.3
14.3
14.3
pmol/l
0.02
167
1390
15
48
3.29
4.01
1.8
1.5
29.2
22.2
u/l
0.36
15
38
36
184
2.15
3.88
3.6
2.2
4.6
5.4
umol/l
0.38
30
155
118
887
1.75
3.87
4.1
3.3
0.0
0.0
estimate
0.00
27
165
11
29
3.95
3.85
2.2
1.3
—
—
—
0
0
119
899
1.75
3.81
4.2
3.4
0.0
0.0
estimate
0.50
26
166
46
260
1.98
3.80
3.3
2.9
100.8
189.9
ng/l
0.39
28
152
118
891
1.74
3.77
6.5
4.7
0.0
0.0
estimate
0.00
26
170
43
239
2.00
3.71
3.1
2.7
4.8
4.4
e6/l
0.06
16
116
8
12
6.88
3.71
1.5
1.7
—
—
—
0
0
99
715
1.73
3.69
7.2
5.1
1.2
1.2
mmol/l
0.47
82
606
49
289
1.91
3.56
2.0
2.7
566.4
669.5
ng/l
0.23
39
239
11
31
3.69
3.53
1.6
1.2
—
—
—
0
0
11
31
3.69
3.53
1.6
1.2
—
—
—
0
0
9
18
5.17
3.41
1.1
1.2
—
—
—
0
0
23
104
2.36
3.30
4.4
3.4
1.2
1.2
mmol/l
0.01
23
89
10
28
3.70
3.23
2.3
1.3
—
—
—
0
0
71
483
1.71
3.19
2.4
2.9
11.8
19.7
ng/l
2.15
29
257
15
57
2.76
3.03
1.4
1.3
—
8.0
—
0
13
39
226
1.89
2.97
2.5
1.7
—
—
—
0
0
42
250
1.85
2.95
3.1
2.6
0.8
1.0
e6/l
0.18
14
128
20
91
2.32
2.84
2.1
1.4
—
—
—
0
0
18
78
2.43
2.83
2.2
1.4
—
—
—
0
0
8
18
4.58
2.82
2.4
1.6
—
—
—
0
0
28
147
2.04
2.82
3.0
1.7
—
—
—
0
0
12
42
2.97
2.80
1.3
1.2
—
—
—
0
0
14
54
2.71
2.76
1.6
2.6
1.8
1.4
g/l
0.52
14
47
7
14
5.13
2.75
1.3
1.6
—
—
—
0
0
11
37
3.08
2.73
1.3
1.3
—
—
—
0
0
62
422
1.67
2.73
3.6
1.9
—
—
—
0
0
6
10
6.14
2.71
1.3
1.9
—
—
—
0
0
44
275
1.76
2.63
3.1
2.4
2.5
2.4
mmol/l
0.77
34
238
5
7
7.28
2.56
1.0
1.3
2.1
2.5
mg/l
—
5
7
6
11
5.58
2.56
2.7
1.8
—
—
—
0
0
34
199
1.85
2.51
1.4
1.3
143.3
176.7
iu/ml
—
10
87
27
147
1.96
2.47
2.9
1.6
—
—
—
0
0
178
1587
1.80
2.44
3.7
3.3
1.4
1.2
mmol/l
2.23
172
1480
78
576
1.56
2.43
4.0
2.5
27.6
27.3
u/l
0.05
71
551
182
1634
1.85
2.42
17.3
9.4
92.8
90.4
ml/min/173m2
0.80
151
1285
11
40
2.85
2.41
1.1
1.5
—
—
—
0
0
33
194
1.83
2.41
3.1
1.8
29.0
29.2
s
0.05
33
189
5
8
6.37
2.38
3.0
1.4
—
—
—
0
0
59
410
1.61
2.37
3.0
2.0
2.7
2.7
mg/l
0.04
52
346
185
1676
1.87
2.29
4.1
3.7
4.8
4.8
mmol/l
0.04
178
1574
184
1665
1.85
2.28
4.0
3.6
1.6
1.6
mmol/l
0.11
177
1558
16
73
2.29
2.27
1.8
2.2
39.2
40.6
u/l
0.09
16
65
195
1799
2.18
2.27
20.1
10.6
24.0
19.0
mg/l
1.05
161
1346
10
36
2.87
2.23
1.4
1.3
—
113.6
—
0
8
5
9
5.66
2.22
1.4
2.1
—
—
—
0
0
186
1694
1.86
2.18
4.6
4.0
2.9
2.8
mmol/l
0.06
178
1579
24
133
1.91
2.10
1.7
1.2
244.2
294.2
u/ml
0.08
24
121
53
370
1.58
2.07
1.4
1.3
18.4
9.6
u/ml
0.21
12
146
151
1314
1.53
2.03
5.6
3.6
12.1
9.5
mm/h
1.74
142
1199
87
679
1.48
2.02
4.3
3.3
—
—
—
0
0
7
21
3.41
1.98
2.7
1.3
—
—
—
0
0
56
402
1.54
1.93
2.5
1.8
1.2
0.9
mg/l
0.31
41
292
52
370
1.54
1.86
1.4
1.3
30.8
16.5
iu/ml
—
10
110
6
17
3.60
1.85
2.7
1.4
—
—
—
0
0
5
12
4.24
1.83
1.4
1.8
—
—
—
0
0
13
60
2.24
1.82
4.2
1.7
—
—
—
0
0
7
23
3.11
1.81
1.3
1.1
—
—
—
0
0
7
23
3.11
1.81
1.3
1.1
—
—
—
0
0
7
24
2.98
1.74
1.3
1.1
—
—
—
0
0
7
24
2.98
1.74
1.3
1.1
—
—
—
0
0
7
24
2.98
1.74
1.3
1.1
—
—
—
0
0
5
13
3.91
1.72
3.2
1.2
—
—
—
0
0
7
28
2.55
1.46
6.0
2.0
—
—
—
0
0
23
142
1.70
1.46
3.4
2.9
—
—
—
0
0
6
22
2.78
1.44
1.2
1.4
—
—
—
0
0
160
1451
1.43
1.40
3.9
3.7
—
—
—
0
0
177
1639
1.51
1.36
4.3
3.6
5.7
5.6
mmol/l
0.27
166
1518
185
1730
1.58
1.34
6.5
5.0
1.6
1.7
mu/l
1.00
177
1621
58
449
1.40
1.34
3.7
3.7
0.0
0.0
estimate
0.00
26
171
6
25
2.44
1.25
1.0
1.1
—
—
—
0
0
112
971
1.33
1.23
3.5
2.8
75.9
66.1
ug/l
0.23
104
906
22
141
1.63
1.23
3.1
4.2
24.6
9.0
ug/l
0.30
12
111
25
167
1.56
1.19
2.6
2.3
2279.4
4085.4
u/l
0.32
12
72
7
30
2.38
1.13
1.3
1.0
—
—
—
0
0
182
1710
1.48
1.13
20.2
11.6
38.5
39.5
%
1.12
146
1377
5
21
2.41
1.09
1.4
1.2
—
—
—
0
0
13
75
1.78
1.05
1.7
1.7
—
—
—
0
0
159
1467
1.35
1.04
5.3
4.3
39.8
37.7
mmol/mol
1.52
148
1376
102
888
1.29
1.03
5.8
3.8
—
—
—
0
0
12
68
1.81
1.03
1.2
1.3
—
—
—
0
0
7
35
2.03
1.01
1.6
1.7
—
—
—
0
0
9
51
1.80
0.96
3.4
3.2
44.7
44.2
%
—
9
51
9
153
0.57
0.93
1.6
1.4
—
—
—
0
0
9
154
0.57
0.92
1.6
1.4
—
—
—
0
0
9
154
0.57
0.92
1.6
1.4
—
—
—
0
0
9
154
0.57
0.92
1.6
1.4
—
—
—
0
0
8
43
1.89
0.88
2.3
2.2
—
—
—
0
0
6
113
0.52
0.86
1.5
1.4
—
—
—
0
0
10
163
0.59
0.82
1.4
1.5
—
—
—
0
0
20
276
0.70
0.78
1.4
1.5
—
—
—
0
0
20
141
1.46
0.78
2.2
1.7
—
—
—
0
0
12
184
0.63
0.78
1.4
1.4
—
—
—
0
0
6
34
1.79
0.77
2.5
2.4
0.0
0.0
g/l
—
6
34
6
34
1.79
0.77
2.5
2.4
0.0
0.0
g/l
—
6
34
11
67
1.68
0.76
1.6
1.5
—
—
—
0
0
5
24
2.11
0.75
5.0
1.3
—
—
—
0
0
5
24
2.11
0.75
1.6
1.2
—
—
—
0
0
5
24
2.11
0.75
1.6
1.3
—
—
—
0
0
14
203
0.67
0.71
2.0
1.5
—
—
—
0
0
53
450
1.24
0.63
1.6
1.6
1.7
1.3
mmol/l
0.85
44
392
8
53
1.53
0.59
2.4
2.1
0.9
1.1
%
—
8
53
6
35
1.73
0.58
2.7
2.4
0.0
0.0
g/l
—
6
35
6
35
1.73
0.58
2.7
2.4
38.5
39.1
g/l
—
6
35
6
37
1.64
0.56
2.7
2.4
4.1
1.1
g/l
—
6
37
30
242
1.28
0.55
2.5
1.6
1306.9
1107.8
nmol/l
0.52
25
177
129
1208
1.18
0.51
2.9
2.7
34.7
32.2
u/l
0.25
124
1152
11
76
1.47
0.49
1.5
1.9
3.0
3.9
ug/l
0.34
11
65
30
246
1.26
0.49
1.2
1.5
1.4
1.3
%
0.53
24
218
5
33
1.53
0.41
1.2
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
6
43
1.41
0.35
2.3
1.3
4.4
3.7
mmol/l
—
6
36
11
143
0.76
0.33
1.1
1.0
—
—
—
0
0
56
510
1.13
0.30
1.5
1.3
0.5
1.4
u/ml
1.59
18
121
42
468
0.87
0.30
2.7
2.2
—
—
—
0
0
13
104
1.27
0.27
1.3
1.3
290.8
273.7
miu/ml
—
6
53
16
133
1.22
0.25
1.4
1.3
—
—
—
0
0
6
85
0.70
0.24
2.8
2.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
13
108
1.22
0.20
1.4
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
6
49
1.23
0.20
3.8
3.1
27.8
33.8
u/ml
—
6
49
7
60
1.17
0.18
1.4
1.2
—
—
—
0
0
7
60
1.17
0.18
1.4
1.4
—
—
—
0
0
40
432
0.91
0.18
2.4
2.1
—
—
—
0
0
7
62
1.13
0.17
1.3
1.1
—
—
—
0
0
7
63
1.11
0.17
1.3
1.1
—
—
—
0
0
8
68
1.18
0.17
1.5
1.8
—
—
—
0
0
11
93
1.19
0.15
1.2
1.5
—
—
—
0
0
28
299
0.93
0.10
2.2
1.9
—
—
—
0
0
5
44
1.14
0.10
1.2
1.3
—
—
—
0
0
5
65
0.76
0.08
1.8
1.8
—
—
—
0
0
7
68
1.03
0.08
1.1
1.1
—
13.1
—
0
13
9
87
1.04
0.07
2.1
1.8
—
—
—
0
0
12
132
0.90
0.07
1.3
1.6
—
—
—
0
0
17
179
0.95
0.03
8.6
4.4
—
—
—
0
0
55
543
1.02
0.01
1.9
1.6
—
—
—
0
0
56
553
1.02
0.01
1.6
1.5
—
—
—
0
0
11
112
0.98
0.00
2.1
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
6.0
—
0
6
0
6
0.00
0.00
0.0
1.0
—
22.3
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
23
230
1.00
0.00
1.9
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
7.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
1792.1
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint E4_OVARDYSNAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_OVARDYSNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_OVARDYSNAS – Ovarian dysfunction, other/unspecified
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data